Lung cancer symptoms are easy to miss, because most of them look like ordinary chest complaints: a cough that lingers, breathlessness on the stairs, a voice that stays hoarse after a cold. That overlap is why lung cancer is still found late more often than most common cancers. In this article you will learn which signs warrant a visit, who qualifies for low-dose CT screening in the United States, what a lung nodule usually turns out to be, how a diagnosis is confirmed, and why molecular testing now shapes treatment. One point up front, because it changes how people seek care: lung cancer is not only a smoker’s disease, and it is not a punishment for a habit.
What lung cancer symptoms actually look like
Early tumors often sit in lung tissue that has no pain nerves, so they can grow for a long time without announcing themselves. When symptoms appear, they usually come from a tumor irritating an airway, pressing on a structure, or from cancer that has spread. No single symptom is proof of anything; a pattern that persists past a few weeks, or that is new for you, is the signal worth acting on.
Signs in the chest and airways
- A cough that is new, or a long-standing cough that changes in sound, frequency, or severity.
- Coughing up blood, even a streak, which always deserves same-week attention.
- Chest, shoulder, or back pain that does not settle.
- Shortness of breath doing things that used to be easy.
- New wheezing, or a whistle heard on one side only.
- Hoarseness lasting more than three weeks without a sore throat.
- Repeated chest infections, or a pneumonia that keeps returning in the same spot.
Signs when the cancer has spread
Lung cancer sometimes announces itself far from the lung. Bone pain, a persistent headache, new confusion, seizures, unexplained weight loss, or swelling of the face and neck can all be first signs. Some tumors, particularly small cell lung cancer, release hormone-like substances that disturb blood chemistry, which is why a doctor may recheck your total calcium level or review your blood sodium level.
Symptoms that are easy to blame on something else
Most people with these symptoms do not have cancer. A cough that follows a cold and clears within three weeks usually reflects acute bronchitis. A cough with fever, night sweats, and weight loss over months should prompt a doctor to consider pulmonary tuberculosis. Sudden breathlessness with sharp chest pain is a different emergency, and clinicians urgently investigate a possible pulmonary embolism. A scan, not a guess, settles the question.
Why lung cancer happens, and why blame is the wrong frame
Tobacco smoke is the largest single cause, and that is worth saying plainly. It is equally worth saying that a meaningful share of lung cancers occur in people who never smoked; genomic work published in 2025 put that group at roughly a quarter of cases worldwide. Stigma has a real cost: people who feel judged delay describing a cough, and delay is what most reliably makes lung cancer harder to treat. If you smoked, quitting lowers your risk at any age. If you never smoked, your symptoms still count.
Radon, the second leading cause and a testable one
Radon is a colorless, odorless radioactive gas released as uranium breaks down in soil and rock. It seeps into homes through foundation cracks, sump pits, and crawl spaces, and United States health agencies rank it as the second leading cause of lung cancer after smoking. Unlike most risk factors, this one is measurable at home: test kits are sold in hardware stores and offered cheaply by many state radon programs. If levels are high, mitigation is a plumbing-scale job, a sealed pipe and a fan venting soil gas above the roofline, usually installed in a day.
The other contributors
- Secondhand smoke at home or at work, which raises risk modestly but consistently.
- Occupational exposures including asbestos, silica, diesel exhaust, arsenic, chromium, and nickel.
- Outdoor air pollution, particularly fine particles in traffic-heavy and industrial areas.
- A family history of lung cancer in a parent or sibling.
- Prior chest radiation therapy, and scarring lung diseases such as pulmonary fibrosis.
Who should be screened, and what the scan really finds
Screening is the only proven way to catch lung cancer before symptoms appear. The test is a low-dose CT scan: a few minutes on a table, no needle, no dye, and far less radiation than a standard chest CT.
The current United States eligibility criteria
The U.S. Preventive Services Task Force recommends annual low-dose CT screening for adults who meet all three conditions below. Patients can also consult the CDC lung cancer screening guidance.
| Criterion | What it means in practice |
|---|---|
| Age 50 to 80 | Annual screening is offered in this window and generally stops at 81. |
| 20 pack-years or more | One pack-year is a pack a day for a year. Two packs a day for 10 years, or one pack a day for 20 years, both reach 20. |
| Smoking now, or quit within 15 years | Eligibility usually ends once 15 years have passed since quitting. |
Screening is not recommended for people who never smoked, because the benefit has not been shown to outweigh the downsides of scanning a low-risk population. That is a population-level judgment, not a statement about you. If you never smoked but have a strong family history, heavy radon or occupational exposure, or persistent symptoms, raise it with a clinician rather than booking a scan on your own.
What a lung nodule usually turns out to be
The most common result of a screening CT is not cancer. It is a nodule: a small round spot, often only a few millimeters across. Nodules are extremely common, and the large majority are harmless scars from old infections, inflammatory tissue, or benign growths. Radiologists grade them by size and appearance and usually recommend a repeat scan in three, six, or twelve months rather than a biopsy. A nodule that has not grown after two years is generally considered benign, and being asked back for another scan is the expected path, not bad news.
Why almost nobody who qualifies gets screened
Uptake is the weak link. The American Lung Association’s State of Lung Cancer report found that fewer than one in five eligible Americans had been screened, a fraction of the participation seen for breast or colorectal screening. Many were never told they qualify, some fear the result or fear judgment about smoking, and some assume the scan is expensive when it is covered without cost sharing by Medicare and most private insurance for those who qualify. Fewer than a third of United States cases are caught early. Asking whether you meet the criteria at your next appointment is the highest-value action in this article.
How lung cancer is diagnosed, and why no blood test does it
This deserves to be unambiguous: there is no blood test that screens for or diagnoses lung cancer. Not a tumor marker, not a routine panel, not a wellness screen. Diagnosis is imaging plus tissue.
Imaging, then tissue
The usual sequence starts with a chest X-ray or CT, moves to a PET-CT and often a brain MRI to see whether disease has spread, and ends with a biopsy. Tissue can be taken through a bronchoscope, through a needle guided by CT or by ultrasound from inside the airway, or at surgery. A pathologist confirms whether cancer cells are present and what type they are. Without tissue there is no diagnosis and no treatment plan. For a fuller walkthrough, consult the National Cancer Institute’s patient guide to non-small cell lung cancer treatment.
What blood tests actually contribute
Blood work supports care without ever making the diagnosis. Before and during treatment, teams almost always order a complete blood count panel to check whether the bone marrow can tolerate chemotherapy, alongside kidney and liver chemistry. Some reports include a lactate dehydrogenase measurement, a marker of cell turnover that gauges disease burden rather than confirming it. Inflammation panels often include a C-reactive protein test, which rises in infection as readily as in cancer, and oncology teams sometimes track a carcinoembryonic antigen level in people already diagnosed. None are screening tests, and one out-of-range number is not a reason to assume cancer.
The two main types, and why the distinction matters
| Feature | Non-small cell lung cancer | Small cell lung cancer |
|---|---|---|
| Share of cases | Roughly four in five | Roughly one in five or fewer |
| Main subtypes | Adenocarcinoma, squamous cell carcinoma, large cell carcinoma | Treated as a single group |
| Typical pace | Slower growing, more often localized when found | Fast growing, usually spread by diagnosis |
| Molecular testing | Central to treatment choice | Limited role so far |
| First-line approach | Surgery or radiation when early; targeted or immune therapy when advanced | Chemotherapy with immunotherapy, often with radiation |
Biomarker testing, and why it changes the treatment plan
Twenty years ago, advanced lung cancer meant one chemotherapy conversation. Today the biopsy sample from a non-small cell tumor is also sent for molecular testing that reads its genes and proteins, and the result decides the first treatment.
The alterations most often looked for
- EGFR, a growth-signal receptor stuck in the on position, blocked by daily oral drugs.
- ALK and ROS1, rearranged genes that fuse with neighbors and drive growth, each with its own oral inhibitors.
- KRAS, long considered untreatable, now targetable in one specific variant.
- PD-L1, a tumor-surface protein that predicts how well immunotherapy is likely to work.
- Less common targets including BRAF, MET, RET, NTRK, and HER2, each with matched drugs.
These alterations are not inherited and are not something you did; they are acquired by the tumor cells themselves. When a matching alteration is found, a targeted tablet often works better and with fewer side effects than intravenous chemotherapy. That is why guidelines urge waiting for full molecular results before starting treatment in advanced disease, and why it is reasonable to ask whether your tumor has had complete biomarker testing.
Liquid biopsy: real, useful, still limited
A liquid biopsy is a blood test that looks for fragments of tumor DNA in the bloodstream. In advanced lung cancer it has a genuine role: when tissue is scarce or a patient is too unwell for another procedure, it can identify a treatable alteration within days, and it can reveal the mutation behind a treatment losing its effect. It does not find lung cancer in a healthy person or replace tissue when tissue can be obtained, and a negative result does not rule out an alteration, because some tumors shed little DNA.
Treatment today
When the cancer is caught early
Localized non-small cell lung cancer is usually removed surgically, often through small incisions with a camera or a robot, taking a lobe of lung and nearby lymph nodes. People who cannot have surgery may be offered stereotactic body radiotherapy, a few precisely aimed high-dose treatments, and immunotherapy or targeted therapy around surgery is now standard in selected cases. This is where screening pays off, because early disease is where cure is realistic.
When the cancer is advanced
Advanced disease is increasingly managed as a long-term condition. Treatment follows type and molecular profile: a targeted tablet where an alteration is found, immunotherapy alone or with chemotherapy where PD-L1 and other features favor it, chemotherapy where neither applies, and radiation for symptom control. Small cell lung cancer is generally treated with chemotherapy plus immunotherapy.
Living with treatment
Chemotherapy commonly causes anemia, fatigue, and low white cell counts, which is why blood counts are checked before most cycles. Immunotherapy can inflame the thyroid, bowel, skin, or lungs, usually reversibly when reported early. Palliative care alongside active treatment is not a last resort; started early it improves symptoms and quality of life.
When to see a doctor
Use this as rough triage, not a substitute for judgment about your own body.
| Situation | Reasonable timing |
|---|---|
| Coughing up blood, severe breathlessness, sudden sharp chest pain, or fainting | Emergency care the same day |
| Cough, hoarseness, or wheeze lasting more than three weeks | Appointment within a week or two |
| Unexplained weight loss, persistent bone pain, or repeated chest infections | Appointment within a week or two |
| Aged 50 to 80 with 20 pack-years, smoking now or quit within 15 years | Ask about screening at your next routine visit |
| Never smoked, no symptoms, worried about risk | Test your home for radon; raise family history at a routine visit |
Latest scientific advances
These studies come from the past three years, summarized in plain language and listed in the sources below.
A quarter of lung cancers arise in people who never smoked
An international team sequenced the tumors of 871 people with lung cancer who had never smoked, across 28 locations, and reported in 2025 that this group accounts for roughly a quarter of lung cancers worldwide. The damage in their tumors did not carry the fingerprint tobacco leaves behind. What this means for you: a diagnosis in a non-smoker is neither rare nor unexplained. This was a genomic survey, so it changes understanding, not yet treatment.
Air and smoke around us matter more than once thought
A 2023 study proposed that tiny airborne pollution particles do not create the first mutation but nudge already-mutated lung cells into growing, which would help explain lung cancer in never-smokers living in polluted areas. Separately, a 2024 systematic review pooled 97 studies, a systematic review being a structured summary of all the research on a question, and confirmed that breathing other people’s smoke raises risk in never-smokers, more so with heavier exposure. What this means for you: smoke-free homes and cars protect everyone around a smoker, and air quality is a health issue rather than an aesthetic one.
Large-scale screening finds most cancers early, and most findings are not cancer
A 2025 report from a program that scanned 12,773 high-risk adults in London found lung cancer in about two participants per hundred, and roughly four in five of those cancers were caught at the earliest two stages, when surgery is usually possible. About five per hundred had a finding that needed a follow-up scan and proved harmless. What this means for you: if a scan spots something, the odds strongly favor it being benign, and if it is cancer, screening has usually found it early.
Screening people who never smoked is being studied, but is not standard
A Taiwanese cohort study published in 2023 offered low-dose CT to never-smokers aged 55 to 75 who had another risk factor, such as a family history of lung cancer, and found mostly early-stage cancers. What this means for you: research is testing whether screening should extend beyond smoking history, but this has not changed United States recommendations, and a cohort study, meaning a group followed over time, cannot alone prove that screening saves lives here.
Blood-based tumor DNA is expanding beyond mutation matching
A 2024 study of several thousand patients found that detectable tumor DNA in blood also flagged who was at higher risk of a blood clot, and a 2024 review concluded that blood-based DNA profiling looks promising for tracking small cell lung cancer but is not yet routine care. What this means for you: blood tests are becoming a useful companion to tissue testing after diagnosis, but remain unsuitable for finding lung cancer in someone without symptoms. Both findings are early.
Glossary
| Term | Definition |
|---|---|
| Low-dose CT (LDCT) | A quick computed tomography scan of the chest using a fraction of the usual radiation. It is the only screening test proven to reduce lung cancer deaths. |
| Pack-year | A way of measuring lifetime smoking. One pack-year equals one pack a day for one year, so half a pack a day for 20 years also equals 10 pack-years. |
| Pulmonary nodule | A small round spot in the lung seen on a scan. Most are harmless scars or benign growths and are simply rechecked later. |
| Biopsy | Removal of a small piece of tissue so a pathologist can examine the cells. It is the only way to confirm lung cancer. |
| Non-small cell lung cancer (NSCLC) | The larger of the two main groups of lung cancer, including adenocarcinoma and squamous cell carcinoma. |
| Small cell lung cancer (SCLC) | A less common, faster-growing type strongly linked to smoking, usually treated with chemotherapy and immunotherapy. |
| Biomarker testing | Laboratory analysis of tumor tissue for specific genes and proteins, such as EGFR, ALK, ROS1, KRAS, and PD-L1, that determine which treatments are likely to work. |
| Targeted therapy | A drug, often a tablet, that blocks a specific molecular change driving a tumor’s growth. |
| Immunotherapy | Treatment that helps the immune system recognize and attack cancer cells, rather than attacking the cells directly. |
| Liquid biopsy | A blood test that detects fragments of tumor DNA in the bloodstream. It supports treatment decisions after diagnosis but cannot screen for lung cancer. |
Frequently asked questions
What causes lung cancer in people who never smoked?
Several exposures contribute. Radon gas in the home is the largest known one in the United States, followed by secondhand smoke, outdoor air pollution, and workplace substances such as asbestos and diesel exhaust. Family history plays a part, and some tumors carry genetic changes such as EGFR alterations that arise in lung cells without any obvious external trigger. In many individual cases no single cause can be identified, which is frustrating but not unusual. The practical response is to test your home for radon, reduce avoidable exposures, and take persistent respiratory symptoms seriously regardless of smoking history.
Can a blood test tell me whether I have lung cancer?
No. No blood test currently available screens for or diagnoses lung cancer. Tumor markers such as carcinoembryonic antigen can rise in some cancers but also rise with smoking, inflammation, and liver conditions, and they can be normal in people who do have lung cancer. Multi-cancer blood tests are being studied but are not recommended as a substitute for CT screening. Diagnosis requires imaging followed by a tissue biopsy. Blood work still matters during care, for checking organ function and monitoring treatment, but it does not answer the diagnostic question.
How do people usually find out they have lung cancer?
Most commonly, someone sees a doctor about a symptom that has not gone away, such as a cough, breathlessness, or chest pain, and a chest X-ray or CT is ordered. A sizeable minority are found incidentally, when a scan performed for another reason picks up an unexpected spot. A smaller but growing group are found through screening, before any symptom appears, and those cases are typically the earliest and the most treatable. Whichever route, the finding is confirmed with a biopsy before any treatment begins.
Is a lingering smoker’s cough different from a lung cancer cough?
There is no reliable way to tell them apart by sound. What matters is change and duration. A long-standing cough that becomes more frequent, deeper, more painful, or starts bringing up blood, and any cough that persists beyond three weeks, should be assessed. Because a chronic cough is so familiar to long-term smokers, it is often dismissed for months, and that delay is one reason lung cancer is found late. Describing the change to a clinician, rather than the cough itself, usually gets the right test ordered.
Can stage 4 lung cancer be cured?
Stage 4 lung cancer is generally not curable, and it is important not to promise otherwise. It is, however, increasingly treatable. Targeted therapies and immunotherapy have extended survival substantially for many people, and some live for years with the disease controlled rather than eliminated, continuing to work and travel. Outcomes vary widely depending on cancer type, molecular profile, extent of spread, and general health. Complete molecular testing of the tumor is the step most likely to open up an effective option, so it is worth asking whether it has been done.
What can I do to lower my risk?
Quitting smoking is the single most effective step, and risk falls steadily after quitting at any age. Test your home for radon and fix it if levels are high, since this is a common and correctable exposure. Keep homes and cars smoke-free to protect others. Use protective equipment if you work around asbestos, silica, or diesel fumes. Find out whether you meet the criteria for annual low-dose CT screening, and if you do, take it up. Nothing removes risk entirely, but these steps address the largest known contributors.
Sources
- Centers for Disease Control and Prevention — Lung cancer screening — CDC, 2025 — cdc.gov
- National Cancer Institute — Non-small cell lung cancer treatment (PDQ), patient version — National Institutes of Health, 2025 — cancer.gov
- Mayo Clinic — Lung cancer: symptoms and causes — Mayo Clinic, 2025 — mayoclinic.org
- Díaz-Gay M, Zhang T, et al. — The mutagenic forces shaping the genomes of lung cancer in never smokers — Nature, 2025 — doi.org/10.1038/s41586-025-09219-0
- Hill W, Lim EL, et al. — Lung adenocarcinoma promotion by air pollutants — Nature, 2023 — doi.org/10.1038/s41586-023-05874-3
- Possenti I, Romelli M, et al. — Association between second-hand smoke exposure and lung cancer risk in never-smokers: a systematic review and meta-analysis — European Respiratory Review, 2024 — doi.org/10.1183/16000617.0077-2024
- Bhamani A, Creamer A, et al. — Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study — The Lancet Oncology, 2025 — doi.org/10.1016/S1470-2045(25)00082-8
- Chang GC, Chiu CH, et al. — Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan (TALENT): a prospective cohort study — The Lancet Respiratory Medicine, 2023 — doi.org/10.1016/S2213-2600(23)00338-7
- Jee J, Brannon AR, et al. — DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism — Nature Medicine, 2024 — doi.org/10.1038/s41591-024-03195-0
- Behrouzi R, Clipson A, et al. — Cell-free and extrachromosomal DNA profiling of small cell lung cancer — Trends in Molecular Medicine, 2024 — doi.org/10.1016/j.molmed.2024.08.004
Further reading
- Readers comparing screening programs often review colorectal cancer symptoms and screening.
- Early detection changes outcomes elsewhere too, and many readers next review breast cancer symptoms and treatments.
- The liver is another common site of spread, and BloodSense covers liver cancer symptoms and treatments.
- Anyone facing a new set of numbers should read a practical guide to reference ranges and flagged results.
- Treatment monitoring frequently tracks hemoglobin levels.
Understand your lab results with BloodSense
A lung cancer work-up generates a lot of numbers, and most of them are not about the tumor at all. Blood counts, kidney and liver chemistry, calcium, sodium, and inflammation markers are all used to judge whether your body can handle a treatment and how it is responding. BloodSense reads those reports in plain language and shows you what each value means and what to ask your care team about. It helps you understand your results; it does not diagnose, and it does not replace your doctor.
